Page last updated: 2024-11-06

6-pentylpyrone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID33960
CHEMBL ID503899
CHEBI ID66729
SCHEMBL ID968257
MeSH IDM0052968

Synonyms (55)

Synonym
AKOS015839660
2h-pyran-2-one, 6-pentyl-
6-amyl-.alpha.-pyrone
NCI60_041518
5-hydroxy-2,4-decadienoic acid gamma-lactone
27593-23-3
6-amyl-alpha-pyrone
nsc-721361
nsc721361
6-amyl-alpha-pyrone, >=96%, fg
6-pentyl-2h-pyran-2-one
6-amyl-2-pyrone
6-pentyl-2-pyrone
6-pentylpyran-2-one
CHEMBL503899
chebi:66729 ,
6-pentyl-pyran-2-one
NCGC00256764-01
tox21_302570
dtxsid0047589 ,
dtxcid8027589
cas-27593-23-3
6-n-pentyl-alpha-pyrone
unii-8jtw8hl4pj
fema no. 3696
einecs 248-552-3
nsc 721361
5-hydroxy-2,4-decadienoic acid delta-lactone
6-pentyl-alpha-pyrone
8jtw8hl4pj ,
5-hydroxy-2,4-decadienoic acid .delta.-lactone [fhfi]
2,4-decadienoic acid, 5-hydroxy-3-methyl-, .delta.-lactone
5-hydroxy-2,4-decadienoic acid .delta.-lactone
FT-0620947
mfcd00047551
SCHEMBL968257
6-pentyl-.alpha.-pyrone
pyran-2-one, 6-pentyl-
MAUFTTLGOUBZNA-UHFFFAOYSA-N
6-n-amyl .alpha.-pyrone
.alpha.-pyrone, 6-pentyl
2-pyrone, 6-pentyl
6-amyl-a-pyrone
AS-58448
2,4-decadien-5-olide
6-n-pentyl-2h-pyran-2-one
6-amyl-alpha -pyrone
6-pentyl-a-pyrone
6-pentyl-alpha -pyrone
alpha -pyrone, 6-pentyl
6-n-amyl alpha -pyrone
fema 3696
5-hydroxy-2,4-decadienoic acid d-lactone
Q27135350
T70705
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-pyranonesA pyranone based on the structure of 2H-pyran-2-one and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency21.87240.000221.22318,912.5098AID743035
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency25.03210.001022.650876.6163AID1224838; AID1224893
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency27.53570.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency8.70760.023723.228263.5986AID743223
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency19.33120.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1870976Neuroprotective activity against 6-OHDA induced cell death in human SH-SY5Y cells preincubated with 6-hyrdoxydopamine followed by compound addition and measured after 24 hrs by MTT assay2022Journal of natural products, 08-26, Volume: 85, Issue:8
Syzysamalactone, an Unusual 11-Carbon δ-Lactone Derivative from the Fresh Ripe Fruits of
AID379501Antimicrobial activity against Botrytis cinerea by spore germination assay1999Journal of natural products, May, Volume: 62, Issue:5
Biotransformation of the trichoderma metabolite 6-n-pentyl-2H-pyran-2-one (6PAP) by selected fungal isolates
AID377992Growth inhibition of etiolated wheat coleoptiles at 1000 uM relative to control1999Journal of natural products, Jan, Volume: 62, Issue:1
Koninginin G, a new metabolite from trichoderma aureoviride
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (44.44)18.2507
2000's3 (33.33)29.6817
2010's0 (0.00)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.31 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]